Cargando…

Intravenous contrast-enhanced CT can be used for CT-based attenuation correction in clinical (111)In-octreotide SPECT/CT

BACKGROUND: CT-based attenuation correction (CT-AC) using contrast-enhancement CT impacts (111)In-SPECT image quality and quantification. In this study we assessed and evaluated the effect. METHODS: A phantom (5.15 L) was filled with an aqueous solution of In-111. Three SPECT/CT scans were performed...

Descripción completa

Detalles Bibliográficos
Autores principales: Klausen, Thomas Levin, Mortensen, Jann, de Nijs, Robin, Andersen, Flemming Littrup, Højgaard, Liselotte, Beyer, Thomas, Holm, Søren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545801/
https://www.ncbi.nlm.nih.gov/pubmed/26501805
http://dx.doi.org/10.1186/s40658-015-0108-1
_version_ 1782386787517202432
author Klausen, Thomas Levin
Mortensen, Jann
de Nijs, Robin
Andersen, Flemming Littrup
Højgaard, Liselotte
Beyer, Thomas
Holm, Søren
author_facet Klausen, Thomas Levin
Mortensen, Jann
de Nijs, Robin
Andersen, Flemming Littrup
Højgaard, Liselotte
Beyer, Thomas
Holm, Søren
author_sort Klausen, Thomas Levin
collection PubMed
description BACKGROUND: CT-based attenuation correction (CT-AC) using contrast-enhancement CT impacts (111)In-SPECT image quality and quantification. In this study we assessed and evaluated the effect. METHODS: A phantom (5.15 L) was filled with an aqueous solution of In-111. Three SPECT/CT scans were performed: (A) no IV contrast, (B) with 100-mL IV contrast, and (C) with 200-mL IV contrast added. Scan protocol included a localization CT, a low-dose CT (LD), and a full-dose CT (FD). Phantom, LD and FD scan series were performed at 90, 120, and 140 kVp. Phantom data were evaluated looking at mean counts in a central volume. Ten patients referred for (111)In-octreotide scintigraphy were scanned according to our clinical (111)In-SPECT/CT protocol including a topogram, a LD (140 kVp), and a FD (120 kVp). The FD/contrast-enhanced CT was acquired in both arterial (FDAP) and venous phase (FDVP) following a mono-phasic IV injection of 125-mL Optiray (4.5 mL/s). For patient data, we report image quality, Krenning scores, and mean/max values for liver and tumor regions. RESULTS: Phantoms: in uncorrected emission data, mean counts (average ± SD) decreased with increasing IV concentration: (A) 119 ± 9, (B) 113 ± 8, and (C) 110 ± 9. For all attenuation correction (AC) scans, the mean values increased with increasing iodine concentration. Patients: there were no visible artifacts in single photon emission computed tomography (SPECT) following CT-AC with contrast-enhanced CT. The average score of image quality was 4.1 ± 0.3, 3.8 ± 0.4, and 4.2 ± 0.4 for LD, arterial phase, and venous phase, respectively. A total of 16 lesions were detected. The Krenning scores of 13/16 lesions were identical across all scan series. The max pixel values for the 16 lesions showed generally lower values for LD than for contrast-enhanced CT. CONCLUSIONS: In (111)In-SPECT/CT imaging of phantoms and patients, the use of IV CT contrast did neither degrade the SPECT image quality nor affect the clinical Krenning score. Reconstructed counts in healthy liver tissues were unaffected, and there was a generally lower count value in lesions following CT-AC based on the LD non-enhanced images. Overall, for clinical interpretation, no separate low-dose CT is required for CT-AC in (111)In-SPECT/CT.
format Online
Article
Text
id pubmed-4545801
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-45458012015-08-26 Intravenous contrast-enhanced CT can be used for CT-based attenuation correction in clinical (111)In-octreotide SPECT/CT Klausen, Thomas Levin Mortensen, Jann de Nijs, Robin Andersen, Flemming Littrup Højgaard, Liselotte Beyer, Thomas Holm, Søren EJNMMI Phys Original Research BACKGROUND: CT-based attenuation correction (CT-AC) using contrast-enhancement CT impacts (111)In-SPECT image quality and quantification. In this study we assessed and evaluated the effect. METHODS: A phantom (5.15 L) was filled with an aqueous solution of In-111. Three SPECT/CT scans were performed: (A) no IV contrast, (B) with 100-mL IV contrast, and (C) with 200-mL IV contrast added. Scan protocol included a localization CT, a low-dose CT (LD), and a full-dose CT (FD). Phantom, LD and FD scan series were performed at 90, 120, and 140 kVp. Phantom data were evaluated looking at mean counts in a central volume. Ten patients referred for (111)In-octreotide scintigraphy were scanned according to our clinical (111)In-SPECT/CT protocol including a topogram, a LD (140 kVp), and a FD (120 kVp). The FD/contrast-enhanced CT was acquired in both arterial (FDAP) and venous phase (FDVP) following a mono-phasic IV injection of 125-mL Optiray (4.5 mL/s). For patient data, we report image quality, Krenning scores, and mean/max values for liver and tumor regions. RESULTS: Phantoms: in uncorrected emission data, mean counts (average ± SD) decreased with increasing IV concentration: (A) 119 ± 9, (B) 113 ± 8, and (C) 110 ± 9. For all attenuation correction (AC) scans, the mean values increased with increasing iodine concentration. Patients: there were no visible artifacts in single photon emission computed tomography (SPECT) following CT-AC with contrast-enhanced CT. The average score of image quality was 4.1 ± 0.3, 3.8 ± 0.4, and 4.2 ± 0.4 for LD, arterial phase, and venous phase, respectively. A total of 16 lesions were detected. The Krenning scores of 13/16 lesions were identical across all scan series. The max pixel values for the 16 lesions showed generally lower values for LD than for contrast-enhanced CT. CONCLUSIONS: In (111)In-SPECT/CT imaging of phantoms and patients, the use of IV CT contrast did neither degrade the SPECT image quality nor affect the clinical Krenning score. Reconstructed counts in healthy liver tissues were unaffected, and there was a generally lower count value in lesions following CT-AC based on the LD non-enhanced images. Overall, for clinical interpretation, no separate low-dose CT is required for CT-AC in (111)In-SPECT/CT. Springer International Publishing 2015-02-12 /pmc/articles/PMC4545801/ /pubmed/26501805 http://dx.doi.org/10.1186/s40658-015-0108-1 Text en © Klausen et al.; licensee Springer. 2015 This is an open access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
spellingShingle Original Research
Klausen, Thomas Levin
Mortensen, Jann
de Nijs, Robin
Andersen, Flemming Littrup
Højgaard, Liselotte
Beyer, Thomas
Holm, Søren
Intravenous contrast-enhanced CT can be used for CT-based attenuation correction in clinical (111)In-octreotide SPECT/CT
title Intravenous contrast-enhanced CT can be used for CT-based attenuation correction in clinical (111)In-octreotide SPECT/CT
title_full Intravenous contrast-enhanced CT can be used for CT-based attenuation correction in clinical (111)In-octreotide SPECT/CT
title_fullStr Intravenous contrast-enhanced CT can be used for CT-based attenuation correction in clinical (111)In-octreotide SPECT/CT
title_full_unstemmed Intravenous contrast-enhanced CT can be used for CT-based attenuation correction in clinical (111)In-octreotide SPECT/CT
title_short Intravenous contrast-enhanced CT can be used for CT-based attenuation correction in clinical (111)In-octreotide SPECT/CT
title_sort intravenous contrast-enhanced ct can be used for ct-based attenuation correction in clinical (111)in-octreotide spect/ct
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545801/
https://www.ncbi.nlm.nih.gov/pubmed/26501805
http://dx.doi.org/10.1186/s40658-015-0108-1
work_keys_str_mv AT klausenthomaslevin intravenouscontrastenhancedctcanbeusedforctbasedattenuationcorrectioninclinical111inoctreotidespectct
AT mortensenjann intravenouscontrastenhancedctcanbeusedforctbasedattenuationcorrectioninclinical111inoctreotidespectct
AT denijsrobin intravenouscontrastenhancedctcanbeusedforctbasedattenuationcorrectioninclinical111inoctreotidespectct
AT andersenflemminglittrup intravenouscontrastenhancedctcanbeusedforctbasedattenuationcorrectioninclinical111inoctreotidespectct
AT højgaardliselotte intravenouscontrastenhancedctcanbeusedforctbasedattenuationcorrectioninclinical111inoctreotidespectct
AT beyerthomas intravenouscontrastenhancedctcanbeusedforctbasedattenuationcorrectioninclinical111inoctreotidespectct
AT holmsøren intravenouscontrastenhancedctcanbeusedforctbasedattenuationcorrectioninclinical111inoctreotidespectct